Platelet-activating factor and distinct chemokines are elevated in mucosal biopsies of erosive compared with non-erosive reflux disease patients and controls

Neurogastroenterology and Motility

Volumn 24, Issue 10, 2012, Pages 943-e463

  Altomare, A ^a   Ma, J ^b,c   Guarino, M P L ^a   Cheng, L ^c   Rieder, F ^d   Ribolsi, M ^a   Fiocchi, C ^d   Biancani, P ^c   Harnett, K ^c   Cicala, M ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b JILIN UNIVERSITY   (China)

^c BROWN UNIVERSITY   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Chemokines; Esophageal inflammation; Gastro esophageal reflux disease; Platelet activating factor

Indexed keywords

ACYLTRANSFERASE; CHEMOKINE; EOTAXIN; EOTAXIN 2; EOTAXIN 3; HISTAMINE H2 RECEPTOR ANTAGONIST; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTON PUMP INHIBITOR; THROMBOCYTE ACTIVATING FACTOR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; ESOPHAGUS BIOPSY; ESOPHAGUS MUCOSA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; NON EROSIVE REFLUX DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REFLUX ESOPHAGITIS; UPREGULATION;

EID: 84866273568     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/j.1365-2982.2012.01963.x     Document Type: Article

References (49)

1. Camilleri M, Dubois D, Coulie B et al. Prevalence and socioeconomic impact of upper gastrointestinal disorders in the United States: results of the US Upper Gastrointestinal Study. Clin Gastroenterol Hepatol 2005; 3: 543-52.
2. Locke GR III, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ III. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997; 112: 1448-56.
3. Dent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2005; 54: 710-7.
4. Fass R, Ofman JJ. Gastroesophageal reflux disease - should we adopt a new conceptual framework? Am J Gastroenterol 2002; 97: 1901-9.
5. Armstrong D. Endoscopic evaluation of gastro-esophageal reflux disease. Yale J Biol Med 1999; 72: 93-100.
6. Knowles CH, Aziz Q. Visceral hypersensitivity in non-erosive reflux disease. Gut 2008; 57: 674-83.
7. Guarino MP, Cheng L, Ma J et al. Increased TRPV1 gene expression in esophageal mucosa of patients with non-erosive and erosive reflux disease. Neurogastroenterol Motil 2010; 22: 746-51.
8. Ma J, Altomare A, Rieder F, Behar J, Biancani P, Harnett KM. ATP: a mediator for HCl-induced TRPV1 activation in esophageal mucosa. Am J Physiol Gastrointest Liver Physiol 2011; 301: G1075-82.
9. Cheng L, de la Monte S, Ma J et al. HCl-activated neural and epithelial vanilloid receptors (TRPV1) in cat esophageal mucosa. Am J Physiol Gastrointest Liver Physiol 2009; 297: G135-43.
10. 2 by peripheral blood leukocytes. Am J Physiol Gastrointest Liver Physiol 2010; 299: G791-8.
11. Bertrand PP. ATP and sensory transduction in the enteric nervous system. Neuroscientist 2003; 9: 243-60.
12. Burnstock G. Purines and sensory nerves. Handbook Experiment Pharmacol 2009; 194: 333-92.
13. Kato M, Kita H, Tachibana A, Hayashi Y, Tsuchida Y, Kimura H. Dual signaling and effector pathways mediate human eosinophil activation by platelet-activating factor. Int Arch Allergy Immunol 2004; 134: 37-43.
14. Shindou H, Hishikawa D, Nakanishi H et al. A single enzyme catalyzes both platelet-activating factor production and membrane biogenesis of inflammatory cells. Cloning and characterization of acetyl-CoA:LYSO-PAF acetyltransferase. J Biol Chem 2007; 282: 6532-9.
15. Paterson WG, Kieffer CA, Feldman MJ, Miller DV, Morris GP. Role of platelet-activating factor in acid-induced esophageal mucosal injury. Dig Dis Sci 2007; 52: 1861-6.
16. Isomoto H, Saenko VA, Kanazawa Y et al. Enhanced expression of interleukin-8 and activation of nuclear factor kappa-B in endoscopy-negative gastroesophageal reflux disease. Am J Gastroenterol 2004; 99: 589-97.
17. Souza RF, Huo X, Mittal V et al. Gastroesophageal reflux might cause esophagitis through a cytokine-mediated mechanism rather than caustic acid injury. Gastroenterology 2009; 137: 1776-84.
18. Fiocca R, Mastracci L, Engstrom C et al. Long-term outcome of microscopic esophagitis in chronic GERD patients treated with esomeprazole or laparoscopic antireflux surgery in the LOTUS trial. Am J Gastroenterol 2010; 105: 1015-23.
19. Fitzgerald RC, Onwuegbusi BA, Bajaj-Elliott M, Saeed IT, Burnham WR, Farthing MJ. Diversity in the oesophageal phenotypic response to gastro-oesophageal reflux: immunological determinants. Gut 2002; 50: 451-9.
20. Isomoto H, Wang A, Mizuta Y et al. Elevated levels of chemokines in esophageal mucosa of patients with reflux esophagitis. Am J Gastroenterol 2003; 98: 551-6.
21. Yoshida N, Uchiyama K, Kuroda M et al. Interleukin-8 expression in the esophageal mucosa of patients with gastroesophageal reflux disease. Scand J Gastroenterol 2004; 39: 816-22.
22. Monkemuller K, Wex T, Kuester D et al. Interleukin-1beta and interleukin-8 expression correlate with the histomorphological changes in esophageal mucosa of patients with erosive and non-erosive reflux disease. Digestion 2009; 79: 186-95.
23. Okada S, Kita H, George TJ, Gleich GJ, Leiferman KM. Transmigration of eosinophils through basement membrane components in vitro: synergistic effects of platelet-activating factor and eosinophil-active cytokines. Am J Respir Cell Mol Biol 1997; 16: 455-63.
24. Sigal CE, Valone FH, Holtzman MJ, Goetzl EJ. Preferential human eosinophil chemotactic activity of the platelet-activating factor (PAF) 1-0-hexadecyl-2-acetyl-sn-glyceryl-3-phosphocholine (AGEPC). J Clin Immunol 1987; 7: 179-84.
25. Lampinen M, Carlson M, Hakansson LD, Venge P. Cytokine-regulated accumulation of eosinophils in inflammatory disease. Allergy 2004; 59: 793-805.
26. Lamouse-Smith ES, Furuta GT. Eosinophils in the gastrointestinal tract. Current Gastroenterol Rep 2006; 8: 390-5.
27. Wiklund IK, Junghard O, Grace E et al. Quality of Life in Reflux and Dyspepsia patients. Psychometric documentation of a new disease-specific questionnaire (QOLRAD). Eur J Surg Suppl 1998; 583: 41-9.
28. Modlin IM, Hunt RH, Malfertheiner P et al. Diagnosis and management of non-erosive reflux disease - the Vevey NERD Consensus Group. Digestion 2009; 80: 74-88.
29. Wardlaw AJ, Moqbel R, Cromwell O, Kay AB. Platelet-activating factor. A potent chemotactic and chemokinetic factor for human eosinophils. J Clin Invest 1986; 78: 1701-6.
30. Snyder F. Platelet-activating factor and its analogs: metabolic pathways and related intracellular processes. Biochim Biophys Acta 1995; 1254: 231-49.
31. Harada A, Sekido N, Akahoshi T, Wada T, Mukaida N, Matsushima K. Essential involvement of interleukin-8 (IL-8) in acute inflammation. J Leukoc Biol 1994; 56: 559-64.
32. Zwahlen R, Walz A, Rot A. In vitro and in vivo activity and pathophysiology of human interleukin-8 and related peptides. Int Rev Exp Pathol 1993; 34: 27-42.
33. Isomoto H, Nishi Y, Kanazawa Y et al. Immune and inflammatory responses in GERD and lansoprazole. J Clin Biochem Nutr 2007; 41: 84-91.
34. Oh DS, DeMeester SR, Vallbohmer D et al. Reduction of interleukin 8 gene expression in reflux esophagitis and Barrett's esophagus with antireflux surgery. Arch Surg 2007; 142: 554-9.
35. Rankin SM, Conroy DM, Williams TJ. Eotaxin and eosinophil recruitment: implications for human disease. Mol Med Today 2000; 6: 20-7.
36. Badewa AP, Hudson CE, Heiman AS. Regulatory effects of eotaxin, eotaxin-2, and eotaxin-3 on eosinophil degranulation and superoxide anion generation. Exp Biol Med 2002; 227: 645-51.
37. Bhattacharya B, Carlstein J, Sabo E et al. Increased expression of eotaxin-3 distinguishes between eosinophilic esophagitis and gastroesophageal reflux diseases. Hum Pathol 2007; 38: 1744-53.
38. Blanchard C, Stucke EM, Rodriguez-Jimenez B et al. A striking local esophageal cytokine expression profile in eosinophilic esophagitis. J Allergy Clin Immunol 2011; 127: 208-17.
39. Huang JJ, Joh JW, Fuentebella J et al. Eotaxin and FGF enhance signaling through an extracellular signal-related kinase (ERK)-dependent pathway in the pathogenesis of Eosinophilic esophagitis. Allergy Asthma Clin Immunol 2010; 6: 25.
40. Baggiolini M, Loetscher P, Moser B. Interleukin-8 and the chemokine family. Int J Immunopharmacol 1995; 17: 103-8.
41. Mukaida N, Harada A, Yasumoto K, Matsushima K. Properties of pro-inflammatory cell type-specific leukocyte chemotactic cytokines, interleukin 8 (IL-8) and monocyte chemotactic and activating factor (MCAF). Microbiol Immunol 1992; 36: 773-89.
42. Hamaguchi M, Fujiwara Y, Yakashima T et al. Increased expression of cytochines and adhesion molecules in rat chronic esophagitis. Digestion 2003; 68: 189-97.
43. Ismail-Beigi F, Horton PF, Pope CE II. Histological consequences of gastroesophageal reflux in man. Gastroenterology 1970; 58: 163-74.
44. Kobayashi S, Kasugai T. Endoscopic and biopsy criteria for the diagnosis of esophagitis with a fiberoptic esophagoscope. Am J Dig Dis 1974; 19: 345-52.
45. Frierson HF Jr. Histology in the diagnosis of reflux esophagitis. Gastroenterol Clin North Am 1990; 19: 631-44.
46. Barlow WJ, Orlando RC. The pathogenesis of heartburn in nonerosive reflux disease: a unifying hypothesis. Gastroenterology 2005; 128: 771-8.
47. Bertrand PP, Bornstein JC. ATP as a putative sensory mediator: activation of intrinsic sensory neurons of the myenteric plexus via P2X receptors. J Neurosci 2002; 22: 4767-75.
48. Burnstock G. Purinergic mechanosensory transduction and visceral pain. Molecular pain 2009; 5: 69.
49. Mihara H, Boudaka A, Sugiyama T, Moriyama Y, Tominaga M. Transient receptor potential vanilloid 4 (TRPV4)-dependent calcium influx and ATP release in mouse oesophageal keratinocytes. J Physiol 2011; 589: 3471-82.